Virus News and Research

Latest Virus News and Research

Researchers find gene regulator that plays key role in DS-AMKL

Between 5 and 10 percent of babies with Down syndrome develop a transient form of leukemia that usually resolves on its own. However, for reasons that haven't been clear, 20 to 30 percent of these babies progress to a more serious leukemia known as Down syndrome acute megakaryoblastic leukemia (DS-AMKL), which affects the blood progenitor cells that form red blood cells and platelets.

1 Mar 2010

Widespread cases of flu plunge from 49 to zero

Normally, this is the peak period for the flu in the United States. But that just doesn't seem to be the case this year.

27 Feb 2010

Fact-checks of the bipartisan health care summit

News outlets fact-check the bipartisan health care summit and provide analyses of the messaging and poll numbers lawmakers used during the six-hour event.

27 Feb 2010

UCLA School of Nursing selects CytoCore's PadKit Collection Kit for comparative cytology study of cervical cancer

CytoCore Inc., the developer of cost-effective products used in the practice of cytology for the detection and diagnosis of cancer and cancer related diseases, announced today that PadKit® Collection Kit, a transport kit using an intralabial device for the collection of gynecological samples, has been selected by the UCLA School of Nursing as the sample collection system for a comparative cytology study of cervical cancer.

26 Feb 2010

Cause of multiple sclerosis: Researchers test autoimmune hypothesis

A non-pathogenic bacterium is capable to trigger an autoimmune disease similar to the multiple sclerosis in the mouse, the model animal which helps to explain how human diseases work. This is what a group of researchers from the Catholic University of Rome, led by Francesco Ria (Institute of General Pathology) and Giovanni Delogu (Institute of Microbiology), have explained for the first time in a recently published article on the Journal of Immunology.

26 Feb 2010

MetLife Foundation Awards for Medical Research in Alzheimer's Disease: Four scientists honored

Complementary approaches to Alzheimer's research were recognized as four scientists received the prestigious MetLife Foundation Awards for Medical Research in Alzheimer's Disease in Washington, D.C.

26 Feb 2010

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.

25 Feb 2010

CDC ACIP's vote for universal influenza vaccination recommendation: FFF endorses

Families Fighting Flu (FFF) fully supports today's vote by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) to expand the current influenza vaccination recommendations to include all adults aged 19 to 49 years of age. Previous recommendations included all other age groups with the exception of this new adult population. This new recommendation will be implemented beginning with the 2010-2011 influenza season.

25 Feb 2010

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

HIV/AIDS remains one of the world's most significant public health challenges, particularly in developing countries. The Human Immunodeficiency Virus (HIV-1), the variant responsible for the pandemic, has the ability to infect different cell types such as T cells, macrophages and dendritic cells (DC). These latter cells are crucial in the defense against infectious agents and play a major role in viral pathogenesis.

25 Feb 2010

American Lung Association supports ACIP's recommendations for universal influenza immunization

The American Lung Association supports the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices' (ACIP) vote today that recommends universal influenza immunization with seasonal influenza vaccine.

25 Feb 2010

Chilean hospital's early use of antiviral treatment and aggressive measures helped reduce H1N1 cases

A Chilean hospital's early use of antiviral treatment in influenza patients and other aggressive measures helped reduce the number of severe H1N1 cases and related deaths. Those are the findings of a new study, now available online (http://www.journals.uchicago.edu/doi/abs/10.1086/650750), published in the March 15, 2010 issue of Clinical Infectious Diseases.

25 Feb 2010

Nevirapine taken to protect fetus from HIV should be avoided for one year after childbirth, say researchers

Women given the human immunodeficiency virus (HIV) prevention drug nevirapine to protect their fetus should not use an HIV-drug regimen that contains nevirapine for at least one year after childbirth, say researchers at the University of Alabama at Birmingham.

25 Feb 2010

Anadys Pharmaceuticals' ANA598 combination demonstrates 73% cEVR in ongoing Phase II study for HCV

Anadys Pharmaceuticals, Inc. today announced preliminary results from an ongoing Phase II study demonstrating that 73% of hepatitis C patients treated with 200 mg ANA598 twice daily in combination with pegylated interferon and ribavirin (SOC) achieved undetectable levels of virus (<15 IU/mL) at week 12, known as complete Early Virological Response or cEVR.

25 Feb 2010

Lack of knowledge and awareness impeding efforts to control HBV and HCV

A recent report by the Institute of Medicine (IOM) confirmed that 3.5 to 5.3 million people (1-2 % of the U.S. population) have chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections. Despite efforts by federal, state and local government agencies to control and prevent these diseases, they remain a serious public health concern. The major factor impeding efforts to control HBV and HCV is lack of knowledge and awareness among health care providers, social service professionals, members of the public, and policy-makers.

24 Feb 2010

IBM Maximo software helps GNL ensure optimal performance of equipment in fight against emerging infectious diseases

In the fight against emerging infectious diseases, The Galveston National Laboratory (GNL), one of two National Institutes of Health funded bio-containment laboratories in the United States, is benefiting from IBM software to ensure the optimal performance of all equipment functioning within its facility. The GNL, which is dedicated to the study and prevention of emerging infectious diseases, will use IBM Maximo Asset Management Software to help automate, manage and ensure the performance of its 3,000 operating assets in one of the world's most complex medical research environments.

24 Feb 2010

FDA recommends H1N1 for inclusion in next year's flu vaccine

The U.S. Food and Drug Administration (FDA) on Monday recommended that the H1N1 (swine flu) strain be added to next year's seasonal flu vaccine, "putting an end to separate shots deployed against the pandemic," Bloomberg reports. The FDA committee voted unanimously to make the H1N1 strain one of the three strains included in the shot, according to the news service. "The panel's recommendations are routinely adopted and used to guide vaccine manufacturers," Bloomberg writes (Randall, 2/22).

24 Feb 2010

NanoViricides files quarterly report with Securities and Exchange Commission

NanoViricides, Inc. has filed its quarterly report with the Securities and Exchange Commission yesterday in a timely fashion.

24 Feb 2010

Genocea Biosciences secures licensing to extensive HSV antigen patent estate

Genocea Biosciences, a leading vaccine discovery and development company, today announced that it has licensed an extensive patent estate from the University of Washington and the Fred Hutchinson Cancer Research Center for 25 pending and issued patents related to herpes simplex virus (HSV) type 2 antigens. The addition of these patents complements the novel antigens discovered by Genocea’s unique and proprietary antigen discovery technology. The combination of Genocea’s novel intellectual property with the patent estate from the University of Washington provides the Company with a broad compendium of HSV antigen patents.

24 Feb 2010

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

At the 17th Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented new data across its broad range of investigational and current medicines for the treatment of HIV/AIDS. Highlighted data at the conference included an oral presentation on the investigational integrase inhibitor, S/GSK1349572, as well as data presentations on SELZENTRY® (maraviroc) and EPZICOM® (abacavir/lamivudine).

24 Feb 2010

Flightless mosquitoes could fight dengue, study says

By rendering female Aedes aegypti mosquitoes - the dengue virus vector - unable to fly, scientists say they may be able to slow the spread of the virus which experts believe "affects up to 100 million people a year and threatens over a third of the world's population," the BBC reports. Currently, there is no treatment for dengue nor a vaccine to protect against the virus.

24 Feb 2010

Virus News and Research

Latest Virus News and Research

Researchers find gene regulator that plays key role in DS-AMKL

Widespread cases of flu plunge from 49 to zero

Fact-checks of the bipartisan health care summit

UCLA School of Nursing selects CytoCore's PadKit Collection Kit for comparative cytology study of cervical cancer

Cause of multiple sclerosis: Researchers test autoimmune hypothesis

MetLife Foundation Awards for Medical Research in Alzheimer's Disease: Four scientists honored

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

CDC ACIP's vote for universal influenza vaccination recommendation: FFF endorses

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

American Lung Association supports ACIP's recommendations for universal influenza immunization

Chilean hospital's early use of antiviral treatment and aggressive measures helped reduce H1N1 cases

Nevirapine taken to protect fetus from HIV should be avoided for one year after childbirth, say researchers

Anadys Pharmaceuticals' ANA598 combination demonstrates 73% cEVR in ongoing Phase II study for HCV

Lack of knowledge and awareness impeding efforts to control HBV and HCV

IBM Maximo software helps GNL ensure optimal performance of equipment in fight against emerging infectious diseases

FDA recommends H1N1 for inclusion in next year's flu vaccine

NanoViricides files quarterly report with Securities and Exchange Commission

Genocea Biosciences secures licensing to extensive HSV antigen patent estate

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

Flightless mosquitoes could fight dengue, study says

A new way of characterising biomolecules eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in